GB9723589D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB9723589D0
GB9723589D0 GBGB9723589.9A GB9723589A GB9723589D0 GB 9723589 D0 GB9723589 D0 GB 9723589D0 GB 9723589 A GB9723589 A GB 9723589A GB 9723589 D0 GB9723589 D0 GB 9723589D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9723589.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB9723589.9A priority Critical patent/GB9723589D0/en
Publication of GB9723589D0 publication Critical patent/GB9723589D0/en
Priority to ARP980105590A priority patent/AR011229A1/es
Priority to MA25336A priority patent/MA26565A1/fr
Priority to CO98065179A priority patent/CO5021135A1/es
Priority to ZA9810125A priority patent/ZA9810125B/xx
Priority to PE1998001065A priority patent/PE20000013A1/es
Priority to JP2000520457A priority patent/JP2001522857A/ja
Priority to APAP/P/2000/001801A priority patent/AP2000001801A0/en
Priority to PCT/EP1998/007021 priority patent/WO1999024449A2/en
Priority to EA200000392A priority patent/EA200000392A1/ru
Priority to BR9813976-2A priority patent/BR9813976A/pt
Priority to PL98340921A priority patent/PL340921A1/xx
Priority to AU20483/99A priority patent/AU2048399A/en
Priority to EP98965151A priority patent/EP1030857B1/en
Priority to AT98965151T priority patent/ATE273990T1/de
Priority to DE1998625780 priority patent/DE69825780T2/de
Priority to EP04076482A priority patent/EP1457495A1/en
Priority to EEP200000285A priority patent/EE200000285A/xx
Priority to US09/530,573 priority patent/US6455510B1/en
Priority to TR2000/02131T priority patent/TR200002131T2/xx
Priority to ES98965151T priority patent/ES2222621T3/es
Priority to IL13596498A priority patent/IL135964A0/xx
Priority to CA002309200A priority patent/CA2309200A1/en
Priority to HR20000275A priority patent/HRP20000275A2/hr
Priority to KR1020007004959A priority patent/KR20010031875A/ko
Priority to SK672-2000A priority patent/SK6722000A3/sk
Priority to HU0004082A priority patent/HUP0004082A2/hu
Priority to CN98812979A priority patent/CN1285843A/zh
Priority to IS5477A priority patent/IS5477A/is
Priority to NO20002361A priority patent/NO20002361L/no
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB9723589.9A 1997-11-08 1997-11-08 Chemical compounds Ceased GB9723589D0 (en)

Priority Applications (30)

Application Number Priority Date Filing Date Title
GBGB9723589.9A GB9723589D0 (en) 1997-11-08 1997-11-08 Chemical compounds
ARP980105590A AR011229A1 (es) 1997-11-08 1998-11-05 Compuestos derivados de adenosina antagonistas en el receptor ai adenosina, procesos para su preparacion, composiciones farmaceuticas que los contieneny su uso en medicina.
MA25336A MA26565A1 (fr) 1997-11-08 1998-11-05 Composes chimiques
CO98065179A CO5021135A1 (es) 1997-11-08 1998-11-05 Compuestos quimicos
ZA9810125A ZA9810125B (en) 1997-11-08 1998-11-05 Chemical compounds.
PE1998001065A PE20000013A1 (es) 1997-11-08 1998-11-05 Derivados de adenosina
CN98812979A CN1285843A (zh) 1997-11-08 1998-11-06 化合物
AT98965151T ATE273990T1 (de) 1997-11-08 1998-11-06 Adenosin a1-rezeptor agonisten
TR2000/02131T TR200002131T2 (tr) 1997-11-08 1998-11-06 Kimyasal bileşikler
PCT/EP1998/007021 WO1999024449A2 (en) 1997-11-08 1998-11-06 Adenosine a1 receptor agonists
EA200000392A EA200000392A1 (ru) 1997-11-08 1998-11-06 Химические соединения
BR9813976-2A BR9813976A (pt) 1997-11-08 1998-11-06 Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um paciente, e, para a preparação de um composto.
PL98340921A PL340921A1 (en) 1997-11-08 1998-11-06 Chemical compounds
AU20483/99A AU2048399A (en) 1997-11-08 1998-11-06 Chemical compounds
EP98965151A EP1030857B1 (en) 1997-11-08 1998-11-06 Adenosine a1 receptor agonists
JP2000520457A JP2001522857A (ja) 1997-11-08 1998-11-06 化合物
DE1998625780 DE69825780T2 (de) 1997-11-08 1998-11-06 Adenosin a1-rezeptor agonisten
EP04076482A EP1457495A1 (en) 1997-11-08 1998-11-06 Adenosine A1 receptor agonists
EEP200000285A EE200000285A (et) 1997-11-08 1998-11-06 Keemilised ühendid
US09/530,573 US6455510B1 (en) 1997-11-08 1998-11-06 Chemical Compounds
APAP/P/2000/001801A AP2000001801A0 (en) 1997-11-08 1998-11-06 Chemical compounds.
ES98965151T ES2222621T3 (es) 1997-11-08 1998-11-06 Agonistas del receptor a1 de adenosina.
IL13596498A IL135964A0 (en) 1997-11-08 1998-11-06 Adenosine a1 receptor agonists
CA002309200A CA2309200A1 (en) 1997-11-08 1998-11-06 Adenosine a1 receptor agonists
HR20000275A HRP20000275A2 (en) 1997-11-08 1998-11-06 Chemical compounds
KR1020007004959A KR20010031875A (ko) 1997-11-08 1998-11-06 화학 화합물
SK672-2000A SK6722000A3 (en) 1997-11-08 1998-11-06 Adenosine derivatives, method for their preparation, pharmaceutical composition containing the same and their use
HU0004082A HUP0004082A2 (hu) 1997-11-08 1998-11-06 Adenozinszármazékok, eljárás előállításukra azokat hatóanyagként tartalmazó gyógyszerkészítmények, valamint ilyen hatóanyagok alkalmazása gyógyszerkészítmények előállítására
IS5477A IS5477A (is) 1997-11-08 2000-05-03 Efnasambönd
NO20002361A NO20002361L (no) 1997-11-08 2000-05-05 Kjemiske forbindelser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9723589.9A GB9723589D0 (en) 1997-11-08 1997-11-08 Chemical compounds

Publications (1)

Publication Number Publication Date
GB9723589D0 true GB9723589D0 (en) 1998-01-07

Family

ID=10821760

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9723589.9A Ceased GB9723589D0 (en) 1997-11-08 1997-11-08 Chemical compounds

Country Status (29)

Country Link
US (1) US6455510B1 (enExample)
EP (2) EP1030857B1 (enExample)
JP (1) JP2001522857A (enExample)
KR (1) KR20010031875A (enExample)
CN (1) CN1285843A (enExample)
AP (1) AP2000001801A0 (enExample)
AR (1) AR011229A1 (enExample)
AT (1) ATE273990T1 (enExample)
AU (1) AU2048399A (enExample)
BR (1) BR9813976A (enExample)
CA (1) CA2309200A1 (enExample)
CO (1) CO5021135A1 (enExample)
DE (1) DE69825780T2 (enExample)
EA (1) EA200000392A1 (enExample)
EE (1) EE200000285A (enExample)
ES (1) ES2222621T3 (enExample)
GB (1) GB9723589D0 (enExample)
HR (1) HRP20000275A2 (enExample)
HU (1) HUP0004082A2 (enExample)
IL (1) IL135964A0 (enExample)
IS (1) IS5477A (enExample)
MA (1) MA26565A1 (enExample)
NO (1) NO20002361L (enExample)
PE (1) PE20000013A1 (enExample)
PL (1) PL340921A1 (enExample)
SK (1) SK6722000A3 (enExample)
TR (1) TR200002131T2 (enExample)
WO (1) WO1999024449A2 (enExample)
ZA (1) ZA9810125B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB0106867D0 (en) 2001-03-20 2001-05-09 Glaxo Group Ltd Process
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
JP4514452B2 (ja) 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション A2aアゴニスト活性を有する2−プロピルアデノシン・アナログおよびその組成物
US7265111B2 (en) 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
EP1375508A1 (en) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
FR2842810B1 (fr) * 2002-07-25 2006-01-27 Inst Nat Sciences Appliq Nouveaux composes gem difluores, leur procedes de preparation et leurs applications.
JP4596913B2 (ja) * 2002-08-15 2010-12-15 ギリアード・パロ・アルト・インコーポレイテッド A1アデノシン受容体の部分および完全アゴニスト
WO2004069185A2 (en) 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1794162A1 (en) * 2004-09-09 2007-06-13 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Purine derivatives as a3 and a1 adenosine receptor agonists
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
JP2011509305A (ja) * 2008-01-09 2011-03-24 ピージーエックスヘルス、リミテッド、ライアビリティー、カンパニー A2arアゴニストによる神経障害性疼痛の髄腔内治療
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
DK2391366T3 (da) 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
HRP20190016T1 (hr) 2009-08-17 2019-03-08 Intellikine, Llc Heterociklički spojevi i njihova upotreba
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン, エルエルシー 複素環化合物およびその使用
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Trk阻害剤としてのピラゾロ[1,5−a]ピリジン
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン, エルエルシー Mtor阻害剤を使用する強化された治療レジメン
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Mdm2抑制劑與BRAF抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
IL321433A (en) 2022-12-16 2025-08-01 Astrazeneca Ab Purines 2,6,9 trimethylated

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575959A (en) * 1969-05-13 1971-04-20 Merck & Co Inc 5'-substituted ribofuranosyl nucleosides
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
AU2022597A (en) 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) * 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
AU2048399A (en) 1999-05-31
EE200000285A (et) 2001-08-15
DE69825780D1 (de) 2004-09-23
CN1285843A (zh) 2001-02-28
WO1999024449A2 (en) 1999-05-20
NO20002361D0 (no) 2000-05-05
HUP0004082A2 (hu) 2001-04-28
AP2000001801A0 (en) 2000-06-30
NO20002361L (no) 2000-07-05
TR200002131T2 (tr) 2001-01-22
ZA9810125B (en) 2000-05-05
EA200000392A1 (ru) 2000-12-25
ATE273990T1 (de) 2004-09-15
PE20000013A1 (es) 2000-01-21
DE69825780T2 (de) 2005-01-13
IS5477A (is) 2000-05-03
AR011229A1 (es) 2000-08-02
WO1999024449A3 (en) 1999-08-19
EP1030857A2 (en) 2000-08-30
BR9813976A (pt) 2000-09-26
JP2001522857A (ja) 2001-11-20
PL340921A1 (en) 2001-03-12
EP1030857B1 (en) 2004-08-18
CO5021135A1 (es) 2001-03-27
HRP20000275A2 (en) 2000-12-31
IL135964A0 (en) 2001-05-20
MA26565A1 (fr) 2004-12-20
US6455510B1 (en) 2002-09-24
KR20010031875A (ko) 2001-04-16
EP1457495A1 (en) 2004-09-15
CA2309200A1 (en) 1999-05-20
ES2222621T3 (es) 2005-02-01
SK6722000A3 (en) 2001-01-18

Similar Documents

Publication Publication Date Title
GB9705361D0 (en) Chemical compounds
GB9704208D0 (en) Chemical compounds
GB9723589D0 (en) Chemical compounds
GB9717804D0 (en) Chemical compounds
GB9708530D0 (en) Chemical compounds
GB9703201D0 (en) Chemical compounds
GB9708119D0 (en) Chemical compounds
GB9705212D0 (en) Chemical compounds
GB9706707D0 (en) Chemical compounds
GB9715768D0 (en) Chemical compounds
GB9711994D0 (en) Chemical compounds
GB9704809D0 (en) Chemical compounds
GB9703200D0 (en) Chemical compounds
GB9708153D0 (en) Chemical compounds
GB9711143D0 (en) Chemical compounds
GB9708115D0 (en) Chemical compounds
GB9707452D0 (en) Chemical compounds
GB9711708D0 (en) Chemical compounds
GB9706668D0 (en) Chemical compounds
GB9711712D0 (en) Chemical compounds
GB9705830D0 (en) Chemical compounds
GB9712270D0 (en) Chemical compounds
GB9713410D0 (en) Chemical compounds
GB9713490D0 (en) Chemical compounds
GB9704224D0 (en) Chemical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)